Arcus Biosciences (RCUS) Tops Q4 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update
February 28, 2023 4:05 PM ESTAt the American Society of Clinical Oncology (ASCO) Plenary session in December 2022, interim data were presented from the ARC-7 study, which demonstrated a median PFS of ~12.0 months for domvanalimab plus zimberelimab vs 5.4 months for zimberelimab alone. In 2022, Arcus and Gilead initiated several new clinical studies for domvanalimab, including two new registrational Phase 3 studies, for a total of four ongoing Phase 3 studies. Data from at least four clinical studies are anticipated in 2023, including updated ARC-7 data at the ASCO Annual Meeting in June... More
